The head of UK-based pharmaceutical company GlaxoSmithKline's corporate venturing unit, Jens Eckstein, becomes one of two directors joining BioHealth Innovation, a public-private partnership focused on commercialising biotech innovations and increasing access to early stage companies in Central Maryland in the US.

Jens Eckstein, president at SR One, UK-based pharmaceutical company GlaxoSmithKline’s independent corporate venturing fund, has joined the board of BioHealth Innovation, a public-private partnership focused on commercialising biotech innovations and increasing access to early stage companies in Central Maryland, US. Eckstein took over as president last year. 

Eckstei joined SR One having worked at venture firm TVM Capital as a general partner since 2007. Eckstein joined TVM as a principal in 2004. At TVM he became chief executive of…